<DOC>
	<DOCNO>NCT01213823</DOCNO>
	<brief_summary>The purpose study estimate relative risk severe hepatic injury hospitalize patient invasive candidiasis candidemia receive anidulafungin , compare patient receive caspofungin and/or micafungin .</brief_summary>
	<brief_title>Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Acutecare inpatient ; Aged 18 year old ; At least one dose echinocandin therapy hospitalization ; Primary secondary ICD9 discharge diagnosis invasive candidiasis / candidemia . &lt; 18 year age ; No record echinocandin therapy hospitalization ; Acetaminophen hepatotoxicity ; Preexisting autoimmune hepatitis ; Autoimmune/metabolic liver disease ; Primary biliary cirrhosis ; Primary sclerosing cholangitis orthotopic liver transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>invasive candidiasis</keyword>
	<keyword>candidemia</keyword>
	<keyword>severe hepatic injury</keyword>
	<keyword>echinocandins</keyword>
	<keyword>anidulafungin</keyword>
	<keyword>caspofungin</keyword>
	<keyword>micafungin</keyword>
</DOC>